Cosmos Health Inc. announced that it will introduce Liv18, a patented botanical blend called BergacynFF®, to the United States during the second quarter of 2026. Liv18 delivers 600 mg of the blend per day and is supported by two independent randomized controlled trials published in 2020 that demonstrated reductions in liver fat accumulation and support for healthy body weight.
The U.S. liver‑health supplement market is estimated at $4.6 billion, with a projected compound annual growth rate of 4.9% through 2035. More than 30% of U.S. adults are affected by metabolic dysfunction‑associated steatotic liver disease, creating a sizable addressable market. While several competitors offer liver‑health products, Liv18 differentiates itself with peer‑reviewed clinical evidence and a proprietary blend that has not been previously available in the market.
Liv18 represents a key element of Cosmos Health’s strategy to expand its branded nutraceutical line into high‑growth U.S. markets. The company expects the launch to add a new revenue stream and reinforce its high‑margin product mix. Liv18 will be manufactured in GMP‑certified, FDA‑registered U.S. facilities and distributed through e‑commerce, retail, and healthcare practitioner channels, reducing tariff exposure and ensuring quality control.
Financially, the nutraceutical segment generated $2.12 million in quarterly revenue from Sky Premium Life products. While prior‑period data for this specific segment are not disclosed, the company’s Q1 2025 owned nutraceuticals revenue was $0.87 million, indicating a growth trajectory for the broader segment.
CEO Greg Siokas stated, "Liv18 represents everything Cosmos stands for: science‑backed, clinically validated, and formulated to make a real difference." The comment underscores management’s confidence in the product’s scientific foundation and market potential.
The launch aligns with Cosmos Health’s broader objective of diversifying revenue and improving profitability. By adding a high‑margin, clinically validated supplement to its portfolio, the company aims to capture a share of the expanding liver‑health market while leveraging its existing manufacturing and distribution infrastructure.
Analysts have begun coverage of Cosmos Health following the announcement, reflecting growing interest in the company’s nutraceutical strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.